DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES
The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; spa |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | O´HEAR Carol, Elaine LI Chi- Chung BENDER Brendan, Christian |
| description | The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by intravenous administration of an anti-CD20/anti-CD3 bispecific antibody (e.g., mosunetuzumab).
La presente invención se refiere al tratamiento de sujetos que tienen trastornos proliferativos celulares positivos para CD20 (por ejemplo, trastornos proliferativos de linfocitos B, tales como linfomas no hodgkinianos). Más específicamente, la invención se refiere al tratamiento de sujetos que tienen un trastorno proliferativo de linfocitos B mediante la administración intravenosa de un anticuerpo biespecífico anti-CD20/anti-CD3 (por ejemplo, mosunetuzumab). |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_MX2023005132A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>MX2023005132A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_MX2023005132A3</originalsourceid><addsrcrecordid>eNrjZHBy8Q_29HNXcPMPUggJcnUM8XX1C1EI9wzxUHD0C_HUdXYxMtCHsowVnDyDA1ydPd08ncGyTv4unq7BPAysaYk5xam8UJqbQcnNNcTZQze1ID8-tbggMTk1L7Uk3jfCyMDI2MDA1NDYyNGYKEUAH7YrKQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES</title><source>esp@cenet</source><creator>O´HEAR Carol, Elaine ; LI Chi- Chung ; BENDER Brendan, Christian</creator><creatorcontrib>O´HEAR Carol, Elaine ; LI Chi- Chung ; BENDER Brendan, Christian</creatorcontrib><description>The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by intravenous administration of an anti-CD20/anti-CD3 bispecific antibody (e.g., mosunetuzumab).
La presente invención se refiere al tratamiento de sujetos que tienen trastornos proliferativos celulares positivos para CD20 (por ejemplo, trastornos proliferativos de linfocitos B, tales como linfomas no hodgkinianos). Más específicamente, la invención se refiere al tratamiento de sujetos que tienen un trastorno proliferativo de linfocitos B mediante la administración intravenosa de un anticuerpo biespecífico anti-CD20/anti-CD3 (por ejemplo, mosunetuzumab).</description><language>eng ; spa</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230525&DB=EPODOC&CC=MX&NR=2023005132A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230525&DB=EPODOC&CC=MX&NR=2023005132A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>O´HEAR Carol, Elaine</creatorcontrib><creatorcontrib>LI Chi- Chung</creatorcontrib><creatorcontrib>BENDER Brendan, Christian</creatorcontrib><title>DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES</title><description>The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by intravenous administration of an anti-CD20/anti-CD3 bispecific antibody (e.g., mosunetuzumab).
La presente invención se refiere al tratamiento de sujetos que tienen trastornos proliferativos celulares positivos para CD20 (por ejemplo, trastornos proliferativos de linfocitos B, tales como linfomas no hodgkinianos). Más específicamente, la invención se refiere al tratamiento de sujetos que tienen un trastorno proliferativo de linfocitos B mediante la administración intravenosa de un anticuerpo biespecífico anti-CD20/anti-CD3 (por ejemplo, mosunetuzumab).</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZHBy8Q_29HNXcPMPUggJcnUM8XX1C1EI9wzxUHD0C_HUdXYxMtCHsowVnDyDA1ydPd08ncGyTv4unq7BPAysaYk5xam8UJqbQcnNNcTZQze1ID8-tbggMTk1L7Uk3jfCyMDI2MDA1NDYyNGYKEUAH7YrKQ</recordid><startdate>20230525</startdate><enddate>20230525</enddate><creator>O´HEAR Carol, Elaine</creator><creator>LI Chi- Chung</creator><creator>BENDER Brendan, Christian</creator><scope>EVB</scope></search><sort><creationdate>20230525</creationdate><title>DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES</title><author>O´HEAR Carol, Elaine ; LI Chi- Chung ; BENDER Brendan, Christian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_MX2023005132A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; spa</language><creationdate>2023</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>O´HEAR Carol, Elaine</creatorcontrib><creatorcontrib>LI Chi- Chung</creatorcontrib><creatorcontrib>BENDER Brendan, Christian</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>O´HEAR Carol, Elaine</au><au>LI Chi- Chung</au><au>BENDER Brendan, Christian</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES</title><date>2023-05-25</date><risdate>2023</risdate><abstract>The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by intravenous administration of an anti-CD20/anti-CD3 bispecific antibody (e.g., mosunetuzumab).
La presente invención se refiere al tratamiento de sujetos que tienen trastornos proliferativos celulares positivos para CD20 (por ejemplo, trastornos proliferativos de linfocitos B, tales como linfomas no hodgkinianos). Más específicamente, la invención se refiere al tratamiento de sujetos que tienen un trastorno proliferativo de linfocitos B mediante la administración intravenosa de un anticuerpo biespecífico anti-CD20/anti-CD3 (por ejemplo, mosunetuzumab).</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; spa |
| recordid | cdi_epo_espacenet_MX2023005132A |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T20%3A58%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=O%C2%B4HEAR%20Carol,%20Elaine&rft.date=2023-05-25&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EMX2023005132A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |